Illuccix is a drug owned by Telix Pharmaceuticals Us Inc. It is protected by 1 US drug patent filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 28, 2035. Details of Illuccix's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11027031 | Kit for radiolabelling |
Jul, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Illuccix's patents.
Latest Legal Activities on Illuccix's Patents
Given below is the list of recent legal activities going on the following patents of Illuccix.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 16 Aug, 2023 | US11027031 |
| Change in Power of Attorney (May Include Associate POA) Critical | 08 Nov, 2022 | US11027031 |
| Change in Power of Attorney (May Include Associate POA) Critical | 19 Sep, 2022 | US11027031 |
| Recordation of Patent Grant Mailed Critical | 08 Jun, 2021 | US11027031 |
| Patent Issue Date Used in PTA Calculation Critical | 08 Jun, 2021 | US11027031 |
| Issue Notification Mailed Critical | 19 May, 2021 | US11027031 |
| Dispatch to FDC | 10 May, 2021 | US11027031 |
| Application Is Considered Ready for Issue Critical | 07 May, 2021 | US11027031 |
| Issue Fee Payment Received Critical | 06 May, 2021 | US11027031 |
| Issue Fee Payment Verified Critical | 06 May, 2021 | US11027031 |
US patents provide insights into the exclusivity only within the United States, but Illuccix is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Illuccix's family patents as well as insights into ongoing legal events on those patents.
Illuccix's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Illuccix's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 28, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Illuccix Generics:
There are no approved generic versions for Illuccix as of now.
Alternative Brands for Illuccix
Illuccix which is used for imaging prostate cancer using PET scan with PSMA targeting in men., has several other brand drugs using the same active ingredient (Gallium Ga-68 Gozetotide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Novartis |
|
About Illuccix
Illuccix is a drug owned by Telix Pharmaceuticals Us Inc. It is used for imaging prostate cancer using PET scan with PSMA targeting in men. Illuccix uses Gallium Ga-68 Gozetotide as an active ingredient. Illuccix was launched by Telix in 2021.
Approval Date:
Illuccix was approved by FDA for market use on 17 December, 2021.
Active Ingredient:
Illuccix uses Gallium Ga-68 Gozetotide as the active ingredient. Check out other Drugs and Companies using Gallium Ga-68 Gozetotide ingredient
Treatment:
Illuccix is used for imaging prostate cancer using PET scan with PSMA targeting in men.
Dosage:
Illuccix is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| N/A | POWDER | Prescription | INTRAVENOUS |